Lilly halts trial of experimental Alzheimers drug
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
Home » Search
Search Results
4,411 results for '\"eli lilly\"'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Lilly to take over development of diabetes drug
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
Company news
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. $7 million and take over the development of a potential diabetes treatment heading into mid-stage clinical testing. According to the Associated Press, Transition said Monday it also could receive up to $240 million in additional payments, plus royalties, if the treatment is eventually approved and sold. It also will pay Indianapolis-based Lilly $14 million in three installments during the mid-stage study. The drug, labeled TT-401, is being developed to treat the most common form of diabetes, type 2, and accompanying obesity. Demand for drugs that treat diabetes is climbing as rising instances of obesity are causing an explosion of diabetes cases globally.
The Indiana University School of Medicine won a $1 million grant from the American Medical Association to launch a virtual health system curriculum for training medical students. The med school is one of 11 grant recipients. IU will use a teaching version of an electronic medical record system to help students use huge quantities of data to make clinical decisions, as well as to monitor the cost of their decisions. Medical school officials said the virtual health system curriculum will be better suited to the changing health care environment its students will encounter after graduation.
Starting July 1, a new state law will allow pharmacists to administer vaccinations for pneumonia, tetanus, diphtheria, acellular pertussis, HPV infections and meningitis, according to The Statehouse File news service. Currently, the only immunizations pharmacists can administer are flu shots. Pharmacists must continue to perform immunizations under physician-monitored guidelines. More than 40 states allow pharmacists to provide immunizations, although requirements for education and oversight vary. In Indiana, pharmacists must undergo immunization training. Already, the state has more than 2,700 pharmacists trained to provide the shots and several hundred new ones are added annually.
Lilly’s pipeline failures concern analysts
The failures raise pressure on Lilly’s experimental diabetes and cancer drugs to make it to market to offset looming patent expirations.
Drugmakers may face ‘pay for delay’ suits, high court rules
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
Lilly’s Zyprexa injection probed by FDA after deaths
Eli Lilly and Co.’s injectable form of the antipsychotic Zyprexa is being investigated by U.S. regulators after two patients died three to four days after receiving the drug.
Pence names Lilly alum Tobias, Pacers’ Morris as IU trustees
Retired Eli Lilly and Co. executive Randall Tobias and Pacers Sports & Entertainment President Jim Morris have been appointed to three-year terms on the Indiana University Board of Trustees.
Lilly’s experimental diabetes drug helps patients lose weight
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
Company news
It looks like Eli Lilly and Co. has a winner. The Indianpaolis-based drugmaker’s experimental diabetes drug dulaglutide helped patients with Type 2 diabetes lose weight while suffering only manageable side effects, according to Phase 3 clinical trial data released over the weekend at the American Diabetes Association meeting in Chicago. According to Bloomberg News, dulaglutide, if approved, may be a significant competitor to Novo Nordisk A/S’ Victoza, which generated $1.64 billion in 2012. A clinical trial comparing the drugs may report results by the end of the year. “We look at the space and we feel we have an opportunity to offer a significant new product,” said Sherry Martin, senior medical director for diabetes development at Indianapolis-based Lilly. The company plans to submit the drug to U.S. regulators for approval by the end of this year. Dulaglutide is projected to sell $835 million in 2018, according to the average of six analysts’ estimates compiled by Bloomberg. Martin said the drug would be the only weekly injection in the class that doesn’t require patients to prepare the dose for administration.
The California Public Employees Retirement System saved $5.5 million, or 19 percent of its affected medical claims, under a two-year pilot project with Indianapolis-based WellPoint Inc. that steered patients away from high-cost health care providers that don’t produce better outcomes. WellPoint executives told Bloomberg News that the cost-capping, or reference-pricing, policy employed in the pilot program is now gaining momentum among employers. The California pension program, known as Calpers, became a partner in the pilot program after a WellPoint analysis found similar hip and knee surgeries cost anywhere from $15,000 to $110,000 per patient, with no difference in patient outcomes, according to Bloomberg. So in 2011, Calpers and WellPoint’s Anthem Blue Cross unit began steering patients toward 46 hospitals that agreed to keep their costs below $30,000—known as the program's “reference price.” If workers went to another provider, then they were responsible for any costs above $30,000. About 400 members opted for the designated hospitals in 2011, a 21-percent increase over previous years. Calpers’ in-patient costs for hip and knee surgeries dropped to an average of $28,695 from $35,400, according to WellPoint. The study was conducted by HealthCore, a research unit owned by WellPoint, and released Sunday at the AcademyHealth Annual Research Meeting in Baltimore.
Researchers at the Indiana University School of Medicine blocked the progression of Type 1 diabetes among newly diagnosed patients using a drug originally sold to treat psoriasis. In a clinical trial involving 49 patients, those who were given the drug alefacept (sold under the brand name Amevive) kept producing the same amount of insulin over the next year, while patients receiving a placebo saw their level of insulin drop over the same period. If the results are repeated in studies involving more patients, the drug could enable Type 1 diabetics to maintain some insulin production and avoid the debilitating complications caused by the disease, said Dr. Mark R. Rigby, a professor of pediatrics at the IU medical school. Nearly 3 million people are estimated to have Type 1 diabetes in the United States. Although the disease can be managed with insulin injections, it cannot be reversed or cured. Long-term complications can include visual impairment, heart disease, stroke, problems in the extremities leading to amputation, and other problems.
An Indiana University School of Medicine researcher has received a $3.8 million three-year grant from the National Institutes of Health to study estrogen as a treatment for schizophrenia using an unreleased drug developed by Eli Lilly and Co. A team led by Dr. Alan Breier, a professor of psychiatry at the IU medical school, will use a drug discovered by Lilly scientists that mimics some of the actions of the hormone estrogen, but without many of the side effects, such as feminization in men and uterine cancer in women. Breier's study is one of nine projects to receive support from a new NIH program called Discovering New Therapeutic Uses for Existing Molecules.
Hostess prepares to open plant despite tax-break question
Hostess Brands LLC has asked the city for a tax abatement on $10 million in new equipment. City officials might decide on July 3, but Hostess is moving ahead with its plans to reopen the plant that closed in November.
Lilly wins patent lawsuit on J&J Alzheimer’s research
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
Me-too diabetes drugs look good enough for Lilly
Eli Lilly and Co. is more than 15 years late to the game in the world of diabetes drugs. And it isn’t bringing much that doctors and patients haven’t already seen. Still, that might be good enough to make a few billion a year.
Lilly Endowment to give $10M to start biosciences institute
The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases.
David and Marilyn Shank are survivors in PR industry
Over the last quarter century, the husband-wife duo has outlived a number of bigger and slicker competitors, even as the Great Recession decimated some bigger PR and advertising shops.
Feds mull covering Alzheimer’s test that uses Lilly’s Amyvid
The $3,000 test for the first time accurately identifies the signature brain plaques of the debilitating disease.
Company news
The federal government is set to decide this month whether the federal Medicare program should pay for a $3,000 test that for the first time accurately identifies the signature brain plaques of Alzheimer’s disease, according to Bloomberg News. The test, approved last year by U.S. regulators, uses Eli Lilly and Co.’s Amyvid imaging agent to trace the brain protein amyloid. Alzheimer’s disease affects 5 million Americans, a number that patient advocates say could double by 2050. But the test is controversial because there are no available treatments that even slow the progression of Alzheimer’s disease. A final decision from the federal Centers for Medicare & Medicaid Services will come July 9. While a negative decision would limit use of the tests, approval would probably lead to coverage from private health insurers, too.
Nyhart Actuary & Employee Benefits plans to expand its Indianapolis headquarters and create as many as 25 jobs here by 2017. The firm will invest $840,000 to lease and equip an additional 8,000 square feet of office space, according to Nyhart CEO Thomas Toten. Nyhart currently is negotiating an expansion of the 20,000 square feet it leases at 8415 Allison Pointe Blvd. in the Castleton area. Nyhart currently has 68 full-time employees in Indianapolis and about another 30 across five other states. The firm already has started hiring additional actuaries, administrators and benefit consultants from college programs for its Indianapolis expansion. Founded in 1943, Nyhart provides consulting services to more than 1,000 public and private companies in 48 states on issues such as pensions, retirement benefits, compensation and other employee benefits. Nyhart has been in growth mode lately. In August, Nyhart acquired San Diego-based The Epler Co., a regional actuarial, employee benefits and compensation strategies firm.
Lilly Endowment Inc. will give $10 million to help start the Indiana Biosciences Institute. The institute is already due to receive $25 million in startup funds from the state. The institute aims to attract 100 new scientists to Indiana to conduct research and development work aimed at launching new therapies for metabolic diseases. The effort has been spearheaded by BioCrossroads, an Indianapolis-based life sciences organization, and has received significant support from Gov. Mike Pence and John Lechleiter, the CEO of Eli Lilly and Co. The institute needs to raise $15 million over the next year or so to fully fund its startup efforts. Beyond that, the institute hopes to raise an endowment of $310 million to help fund its operations. It also hopes its researchers attract steady grants from life sciences research companies, such as Indianapolis-based Lilly and Bloomington-based Cook Group Inc.
Eli Lilly and Co. won a United Kingdom patent lawsuit against a Johnson & Johnson unit over a potential treatment for Alzheimer’s disease, according to Bloomberg News. A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London on June 25. Both companies are developing treatments targeting the buildup of plaque in patients’ brains that’s linked to the condition. Companies developing the first treatments for Alzheimer’s are competing for what might be a $20 billion market, according to a report last year by Deutsche Bank AG analysts.
The head of the state Family and Social Services Administration said the federal government is expected to approve an extension of the Healthy Indiana Plan, but a request to use the plan for an Indiana Medicaid expansion could take much longer. According to the Associated Press, FSSA Secretary Debra Minott said Gov. Mike Pence directed her and others to ensure those already enrolled in HIP are secure before negotiating an expansion through the program. Roughly 40,000 low-income residents are enrolled in the program, which operates under a federal waiver. But the waiver is set to expire at the end of the year, potentially leaving enrollees without coverage. Pence resubmitted an application with the Centers for Medicare and Medicaid Services in April seeking to use the state's hybrid health savings account plan as the vehicle for Medicaid expansion. CMS rejected an earlier request from former Gov. Mitch Daniels, citing concerns about the premium paid by members and a need for improved coverage. The expansion would cover residents earning up to 138 percent of the federal poverty level, using new funds authorized by Obamacare.
Miami man pleads guilty to $90M Lilly drug heist
Thieves broke into the Connecticut warehouse of Indianapolis-based Eli Lilly and Co. in 2010 by scaling an exterior wall and cutting a hole in the roof. They lowered themselves to the floor and disabled alarms before using a forklift to load pallets of drugs into a getaway vehicle.
Universities’ patents often lack commercial applications
The state's universities crank out patents that find their way to pharmaceutical, prosthetics and surgery technology companies. But they also generate reams of patents in areas with few industrial applications.
Firms unravel implications of same-sex court ruling
Judges have spoken and people have celebrated, but human resources departments remain confounded on what will change for their companies with the U.S. Supreme Court’s ruling on the Defense of Marriage Act.
Stevens’ move comes as surprise to Bulldogs
On Wednesday, the 36-year-old Stevens stunned the city of Indianapolis by leaving the tiny school he led to back-to-back national runner-up finishes to take the Celtics job. The news hit hardest inside historic Hinkle Fieldhouse.